Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …

The significant activity of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of
germline BRCA mutation-associated ovarian cancer, which represents∼ 15% of HGS …

Purpose: Hallmarks of germline BRCA1/2-associated ovarian carcinomas include
chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 …

The elucidation of breast cancer subgroups and their molecular drivers requires integrated
views of the genome and transcriptome from representative numbers of patients. We present …

Abstract “Platinum resistant” ovarian cancer was historically defined as disease recurrence
within 6 months of completion of first-line platinum-based chemotherapy, although this is …

Plants generate effective responses to infection by recognizing both conserved and variable
pathogen-encoded molecules. Pathogens deploy virulence effector proteins into host cells …

Summary Trimethyl-lysine (me3) modifications on histones are the most stable epigenetic
marks and they control chromatin-mediated regulation of gene expression. Here, we …

Germline mutations in the BRCA1, BRCA2 and Fanconi anaemia genes confer cancer
susceptibility, and the proteins encoded by these genes have distinct functions in related …

Homologous recombination and DNA repair are important for genome maintenance.
Genetic variations in essential homologous recombination genes, including BRCA1 and …

BRCA1 (BReast‐CAncer susceptibility gene 1) and BRCA2 are tumor suppressor genes, the
mutant phenotypes of which predispose to breast and ovarian cancers. Intensive research …